BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 28, 2018
View Archived Issues
CBT and Zhejiang Bossan announce collaborate to develop combination cancer treatments
Read More
Simple sugar may impair cancer growth in mice
Read More
Alunbrig approved in Europe for patients with ALK+ NSCLC previously treated with crizotinib
Read More
Melinta Therapeutics granted marketing authorization for Vabomere in Europe
Read More
Athenex initiates phase I/II trial of Oraxol in combination with pembrolizumab
Read More
First patient dosed in phase II study of omadacycline in acute pyelonephritis
Read More
Evelo Biosciences announces plans for first monoclonal microbial oncology product candidate
Read More
Phase III CheckMate-451 study of Opdivo with Yervoy in extensive-stage SCLC misses primary endpoint
Read More
Acquist Therapeutics presents data for novel dual XO and URAT1 inhibitor RLBN-1127
Read More
Glenmark Pharmaceuticals discovers NADPH oxidase inhibitors
Read More
Wockhardt describes new antibacterial diazabicyclooctane derivatives
Read More
University of California, Oakland, Istituto Italiano di Tecnologia (IIT) patent RhoJ inhibitors
Read More
Moderna Therapeutics begins phase I study of mRNA-2752 in advanced malignancies
Read More
University of Louisville describes anticancer copper complexes
Read More
ViiV Healthcare presents HIV replication inhibitors
Read More
ER-INP as novel therapeutic strategy for drug-induced acute liver injury
Read More
ET-D5 demonstrates promising in vivo efficacy as potential new anticancer therapy
Read More
First-in-human data for MK-4280 alone or in combination with pembrolizumab
Read More
FDA clears IND for PBCAR-0191 allogeneic CAR T product candidate
Read More
Vertex reports phase III data on VX-659 triple combination regimen for cystic fibrosis
Read More
New phase I trial explores nasal administration of foralumab in healthy volunteers
Read More
Bile acid receptor implicated in hepatic encephalopathy due to liver cirrhosis
Read More
Spark Therapeutics to begin phase I/II study of SPK-8016 gene therapy in hemophilia A
Read More
Preclinical evaluation of zifaxaban, an oral inhibitor of factor Xa for thromboembolic diseases
Read More
New deep vein thrombosis model allows real-time in vivo imaging
Read More
Preclinical results of EAGLE technology targeting glyco-immune checkpoints for cancer treatment
Read More
Phase II trial of bemcentinib/pembrolizumab combination in patients with advanced NSCLC and melanoma
Read More